For sale India Tarceva India Tarceva purchase price 13501239552

India's Tarceva is produced by C Company, the largest oncology drug company in India. It is currently the latest biological targeted therapy drug for lung cancer. It is a targeted therapy drug that clinical studies have proven to be able to significantly prolong the survival of lung cancer patients. & At the request of cancer patients or their families, this site can purchase Indian Tarceva on their behalf, and it is guaranteed to be original and authentic from India
[Chinese name]
& Tarceva
& Erlotinib Hydrochloride Tablets
[English name of the product]

[Manufacturer]
Indian C Pharmaceutical Factory
[Indications]
For use on two or more Third-line treatment of locally advanced or metastatic non-small cell lung cancer after failure of chemotherapy.
[Chemical Composition]
Each tablet contains erlotinib (in the form of erlotinib hydrochloride).
[Pharmacological Actions] The anti-tumor mechanism of
is mainly to inhibit the intracellular phosphorylation of epidermal growth factor tyrosine kinase.
[Drug Interactions]
[Adverse Reactions]
The most common adverse reactions are rash and diarrhea, the incidence rates of rash and diarrhea are % and % respectively, and the median occurrence of rash Time is days, and the median onset time of diarrhea is days. Adverse reactions with an incidence rate greater than % include: rash, diarrhea, decreased appetite, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, and abdominal pain. Pulmonary Toxicity: There are rare reports of severe interstitial lung disease, even death, in treated patients or in patients with other solid tumors. In randomized controlled studies, the incidence rate was .% and was the same in the treatment and placebo groups. Reported include: pneumonia, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory stress syndrome, and pulmonary effusion. Symptoms occurred from the day after treatment to more than one month, with a median onset time of days. Most patients often have confounding factors, such as previous chemotherapy/radiation therapy, existing parenchymal lung disease, lung metastasis or lung infection. When there are new and unexplained pulmonary symptoms, such as dyspnea, cough, fever, etc., examination and evaluation are required. Once diagnosed, continued use should be stopped and appropriate treatment should be taken. Hepatotoxicity: Treatment can cause asymptomatic increases in liver transaminases. Therefore, liver function should be reviewed regularly during treatment, including: transaminases, bilirubin, alkaline phosphatase, etc. If liver function damage is severe, the dose should be reduced or the drug should be discontinued. Liver damage is often temporary or accompanied by liver metastasis. Gastrointestinal bleeding is rarely reported and often occurs in patients taking warfarin at the same time. Therefore, patients taking warfarin or other anticoagulants at the same time should monitor their prothrombin time. Elderly patients: Safety and pharmacokinetics do not differ significantly between young and elderly patients; therefore, no dose adjustment is recommended when used in elderly patients.